Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Summary
This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.
Bill status
in committee
1 of 4 stages cleared
Introduction
Apr 2023
Committee Review
Floor Vote
President
Introduced Apr 19, 2023
Last action Apr 19, 2023
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Apr 19, 2023
Committee
Referred to the House Committee on Energy and Commerce.
lower
Apr 19, 2023
Introduced
Introduced in House
lower
1 primary · 48 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Kathy E. Manning
DDemocratic
Co
Andrea Salinas
DDemocratic
Co
Ayanna Pressley
DDemocratic
Co
Becca Balint
DDemocratic
Co
Betty McCollum
DDemocratic
Co
Bradley Scott Schneider
DDemocratic
Co
Brian Higgins
DDemocratic
Co
Brittany Pettersen
DDemocratic
Co
Chris Pappas
DDemocratic
Co
Christopher R. Deluzio
DDemocratic
Co
Cori Bush
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HRES 309
Scope: US
Hi! I can help you understand HRES 309. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline